Defendant Profile · Consumer Product
QVAR Inhaler Antitrust Class Action Settlement — $35M Teva Fund, Claim by July 31, 2026
Quick answer
QVAR Inhaler Antitrust Class Action Settlement — $35M Teva Fund, Claim by July 31, 2026 has a Corp-Watch grade of A+ based on 1 tracked class action settlements in the Consumer Product industry.
Corporate Responsibility Matrix
Independent trust score from class action track record
A+90/100
A+
A
B
C
D
F
Active suits
1
Total public payouts
$70M
Avg distribution velocity
Insufficient data
Class action score100% weight
90/100
Updated Jun 23, 2026, 9:00 PM. Methodology. Editorial grade — not legal advice.
Tracked cases against this defendant
Related investigations
Defendant FAQ
Questions about QVAR Inhaler Antitrust Class Action Settlement — $35M Teva Fund, Claim by July 31, 2026
- Corp-Watch grades (A+ through F) reflect litigation volume, payout pools, distribution timelines, and public regulatory signals. Grades refresh automatically every six hours.